Syncona Archives

Home Syncona

Latest Posts

News and Trends 12 Jun 2023

Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases

Beacon Therapeutics Holdings Limited has been launched to develop gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors…

June 12, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 13 Oct 2015

The Top 15 European Biotech VCs

Biotech wouldn't exist without Venture Capitalists. These investors bring the cash necessary to run clinical trials or conduct the scaling-up of processes, along with many years of experience. Though admittedly…

October 13, 2015 - 9 minutesmins - By Philip Hemme

News and Trends 24 Oct 2022

Syncona to acquire Applied Genetic Technologies Corporation

Healthcare company Syncona Limited says its newly established portfolio company has agreed to acquire, by a tender offer, all outstanding shares of Applied Genetic Technologies Corporation (AGTC). AGTC is a…

October 24, 2022 - 2 minutesmins - By Jim Cornall

Europe VC top investors biotech life sciences finance

Best in Biotech 12 Apr 2016

18 of the Best European VCs for Biotech in 2016

As Genentech is celebrating its 40th Birthday, it is also the 40th birthday of Biotechnology and the 40th birthday of Biotech Venture Capitalists. These risk investors are deeply linked to…

April 12, 2016 - 10 minutesmins - By Philip Hemme

News and Trends 17 Feb 2020

UK Biotech Closes €50M Series A for GPCR Drug Discovery

Oxford-based OMass Therapeutics has extended its Series A round by €33M to fund the spectrometry-assisted development of drugs targeting G protein-coupled receptors. OMass Therapeutics’s Series A initially raised €17M in…

February 17, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 26 Feb 2019

Immuno-oncology Biotech Raises €31M to Progress T-Cell Boosting Therapy

The Swiss biotech Anaveon closed a very respectable €31M (CHF35M) Series A fundraising round to help progress its T-cell boosting, cancer-fighting treatment to the clinic. The company’s candidate therapy mimics…

February 26, 2019 - 2 minutesmins - By Helen Albert

News and Trends 30 Jun 2017

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that…

June 30, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Mar 2016

CAR-T Startup Gets €51M from Top&New Investors

Autolus (UK) has secured over €51M in a recent series B round, led by the biggest Biotech VC in Europe - and a new player in life science investment. Autolus…

March 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

cambridge epigenix true methyl oxsb seq epigenome sequencing 5mc 5hmc gv sequoia geoff smith

News and Trends 14 Mar 2016

British Startup Raises Millions to Become the Illumina for Epigenetics

Cambridge Epigenetix (UK) wants to unlock the power of the Epigenome and become what Illumina is for NGS. And now, it has gotten the €18.9M and a new CEO needed to…

March 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

nightstarx oxford chroideremia night blindness

News and Trends 11 Nov 2015

Oxford’s Nightstar Gene Therapy for Blindness in Men Shines with $35M Fundraiser

Choroideremia is a rare X-linked recessive retinal disease which eventually leads to blindness. A series B funding round has landed the NightstaRx ('Nightstar') biotech in Oxford an additional $35M for…

November 11, 2015 - 3 minutesmins - By Dani Bancroft

cardiovascular disease heart attack forcefield therapeutics

News and Trends 25 Apr 2022

Forcefield Therapeutics Launched to Treat Heart Attacks with Protein Drugs

The startup Forcefield Therapeutics has been unveiled in the UK with €6M (£5.5M) backing from the investment firm Syncona. The mission is to develop the first drugs to safeguard heart…

April 25, 2022 - 4 minutesmins - By Jonathan Smith

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering